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KEY POINTS

Question: Is collaborative care an effective method to reduce depressive symptoms in older people with low severity depression?

Findings: : In the CASPER randomized trial of 705 participants age 65 and older with sub-threshold depression, those randomized to a collaborative care intervention had lower depression scores, measured by the Patient Health 9-item questionnaire at 4 month follow-up, compared to usual care.  

Meaning: Among older adults with subthreshold depression, a collaborative care intervention reduced depressive symptoms at 4-month follow-up, compared to usual care. The long term efficacy of this intervention is unclear.  


ABSTRACT (350 words)
Importance:  There is little evidence to guide management of depressive symptoms in older people.  
Objective: To evaluate whether a collaborative care intervention can reduce depressive symptoms and prevent more severe depression in older people.  
Design, Setting, Participants: Randomized clinical trial, conducted from 24th May 2011 to 14th Nov 2014 in 32 primary care centers in United Kingdom.  705 participants (344 intervention vs 361 usual care) aged 65 and over with DSM-IV sub-threshold depression were randomized (1:1).  
Intervention: Collaborative care was coordinated by a case manager who assessed functional impairments relating to mood symptoms..  Participants were offered behavioural activation and completed on average 6 weekly sessions.  The control group received usual primary care.
Main Outcomes: Participants were followed up for 12 months.  Primary outcome was self-reported depression severity at 4 months measured by Patient Health Questionnaire-9 items (PHQ-9, range 0-27).  Included among 10 pre-specified secondary outcomes were 12 months PHQ 9, and the proportion meeting criteria for depressive disorder (defined as PHQ9 score >/= 10) at 4 and 12 months.
Results:  705 participants were randomised, 58% female, mean age 77 (SD 7.1).  4 month retention was 83% with higher loss to follow-up in collaborative care (24%) compared to usual care (10%).  Collaborative care resulted in lower PHQ-9 scores as compared to usual care at four months (mean PHQ-9 collaborative care: 5.36; mean usual care: 6.67; mean difference: -1.31, 95% CI: -1.95 to -0.67, p<.001).  Treatment differences remained at twelve months (mean difference: -1.33 points, 95% CI: -2.10 to -0.55).  The proportions of participants meeting criteria for depression at four months were17.2% vs 23.5%, respectively (difference = -6.3%. 95%CI -12.8, 0.2, Relative Risk 0.83, 95% CI: 0.61 to 1.27, p=0.247) and at 12-months were 15.7% vs. 27.8% (difference = -12.1%, 95%CI -19.1, -5.1, Relative Risk 0.65, 95%CI 0.46 to 0.91, p=0.013).
Conclusion and Relevance: Among older adults with sub-threshold depression, collaborative care compared with usual care resulted in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain clinical importance. Although differences persisted through 12 months, findings are limited by attrition, and further research is needed to assess longer-term efficacy. 
Trial Registration: Current Controlled Trials ISRCTN02202951 http://www.isrctn.com/ISRCTN02202951 (​http:​/​​/​www.isrctn.com​/​ISRCTN02202951​)




BACKGROUND
Depression is the second leading cause of disability worldwide.(1)  One in seven older people meet criteria for depression.  Effective therapeutic strategies are needed in older people with depressive symptoms who also have comorbid diseases and impaired quality of life.(2) ADDIN EN.CITE <EndNote><Cite><Author>Rapp</Author><Year>1998</Year><RecNum>2405</RecNum><DisplayText>(3)</DisplayText><record><rec-number>2405</rec-number><foreign-keys><key app="EN" db-id="pw952drr302ez4e9te6xx0p50spxzwtpfxzd">2405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Rapp, S.</author><author>Parsi, S.</author><author>Walsh, D.</author></authors></contributors><titles><title>Psychological dysfunction and physical health among elderly medical inpatients</title><secondary-title>Journal of Consult Clinical Psychology</secondary-title></titles><pages>851-855</pages><volume>56</volume><dates><year>1998</year></dates><urls></urls></record></Cite></EndNote>(3) ADDIN EN.CITE <EndNote><Cite><Author>Chachamovich</Author><Year>2008</Year><RecNum>2391</RecNum><DisplayText>(4)</DisplayText><record><rec-number>2391</rec-number><foreign-keys><key app="EN" db-id="pw952drr302ez4e9te6xx0p50spxzwtpfxzd">2391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Chachamovich, Eduardo</author><author>Fleck, Marcelo</author><author>Laidlaw, Ken</author><author>Power, Mick</author></authors></contributors><titles><title>Impact of Major Depression and Subsyndromal Symptoms on Quality of Life and Attitudes Toward Aging in an International Sample of Older Adults</title><secondary-title>Gerontologist</secondary-title></titles><pages>593-602</pages><volume>48</volume><number>5</number><dates><year>2008</year><pub-dates><date>October 1, 2008</date></pub-dates></dates><label>Dep Elderely</label><urls><related-urls><url>http://gerontologist.gerontologyjournals.org/cgi/content/abstract/48/5/593 </url></related-urls></urls></record></Cite></EndNote>(4)  There is limited research about older people with mild disorders who have insufficient levels of depressive symptoms to meet diagnostic criteria (called ‘sub-clinical’, ‘sub-threshold’ or ‘sub-syndromal’ depression) (5) but also reduced quality of life and function.(4)  Sub-threshold depression is a risk factor for more severe depressive illness.(6)  With increased interest in preventive approaches to depression (7), trials have focused on adults with sub-threshold disorders.(8)  The focus of this research was older people with low level depressive symptoms. 

The prescription of anti-depressants is not recommended as a first line treatment for sub-threshold depression since there is little evidence they are effective.  Psychological therapies may be more appropriate, but higher intensity forms of therapy such as Cognitive Behaviour Therapy, Interpersonal Therapy or Behavioural Activation (BA) are generally reserved for people with more severe disorders.(9)  Collaborative care involves the provision of care by a trained case manager under the principles of chronic disease management.(10)  A meta-analysis reported that collaborative care is effective for people with depression meeting diagnostic thresholds (11), but its ability to prevent depression in high risk populations has not been examined.  The objective of this study was to evaluate the effect of a collaborative care intervention in older people with sub-threshold depression in a UK primary care setting.  

METHODS
This trial was a pragmatic, multi-centre, two-group, parallel, randomized clinical trial.  Older adults with lower severity depressive symptoms recruited in primary care were randomized to receive either usual care from their primary care physician or a collaborative care intervention in addition to their usual primary care.

Recruitment of participants and eligibility criteria
This study was approved by the NHS Leeds East Ethics Committee on 28 September 2010 (10/H1306/61).  Participants age 65 and older from 32 primary care practices gave written informed consent between March 2011 and July 2013 in the North of England, UK.  Prior to the definitive trial an internal pilot was conducted with 100 participants where the age of participants was 75 years and above.  The age cut point was reduced from 75 to 65 following advice from the Trial Steering Committee to align the trial population with an age-specific demarcation in the UK where patients aged 65 and older are treated by older persons’ mental health services.

Potential participants were identified by postal questionnaire and were eligible if they reported depressive symptoms on a standardised brief 2 item case-finding tool (the Whooley questions - Q1: Over the past month have you been bothered by feeling down, depressed or hopeless?  Q2: Over the past month have you been bothered by having little or no interest or pleasure in doing things?) (12) and were found to have sub-threshold depression according to DSM-IV criteria using the Mini International Neuropsychiatric Interview (MINI v5.0) (13), conducted over the phone by researchers trained by clinical co-investigators.  The participants’ Primary Care Physician excluded people with known alcohol dependency; psychosis; recent suicidal risk; significant cognitive impairment; recent bereavement or terminal illness on clinical grounds (based on their knowledge of the patient).  People receiving psychological therapy were excluded.  Participants receiving antidepressants remained eligible.  Ethnicity was recorded by self-report to describe the diversity of participants.  

Randomisation, concealment and blinding
Participants were allocated to collaborative care or usual care by a computer in a 1:1 ratio by simple randomization without blocking or stratification.  Treatment allocation was concealed from study researchers at the point of recruitment using an automated computer data entry system, administered remotely by the York Trials Unit which employed a computer-generated code.  None of the participants, primary care practices or clinicians could be blinded to treatment allocation.  Researchers who assessed outcomes were blind to treatment allocation.  

Intervention (collaborative care) and comparator (usual GP care)
Participants in the intervention group received a programme of collaborative care, designed specifically for older people with sub-threshold depression and to accommodate long term physical health problems (see (15) for an extended description).  Collaborative care was delivered by a case manager (with a background in mental health nursing or a graduate psychologist) over eight weekly sessions.(16)  The intervention consisted of telephone support and session by session symptom monitoring to track treatment response.  The case managers were supervised and corresponded with the primary care physician or older-age psychiatrist where necessary.  The first session was delivered face-to-face and subsequent sessions via telephone.  A computer system was used to monitor care and supervision of case managers was offered by DB, DF, DE, DM, JD and SG.  Participants were offered a structured programme of behavioural activation.(17)  This brief psychological intervention addressed the behavioural deficits of depression such as avoidance of social interaction and the absence of rewarding activities.(18)  Participants already prescribed anti-depressants were encouraged to continue medication and primary care physicians were only encouraged to initiate medication in response to increasing depressive symptoms.(9)

Participants in the control group were allocated to receive usual primary care.  They received no additional care to the usual primary care management of sub-threshold depression.  

Outcomes
The primary outcome was self-reported severity and symptoms of depression, assessed by the Patient Health Questionnaire-9 items (PHQ-9),(19) at four months.  The PHQ-9 has a score range 0 (least depressed) to 27 (most depressed).  Secondary outcomes included the PHQ-9 depression severity at 12 months; and at 4 and 12 months: dichotomised depression according to ‘depression diagnosis’, defined using an optimum cut point of PHQ-9≥10, which has been validated as a sensitive and specific criterion for DSM-IV Major Depressive Disorder.(19)  We also studied a limited range of secondary outcomes of decrements and comorbidities associated with depression, including health-related quality of life measured by the 12 item short form survey (SF-12) mental component scale and physical component scale, score range 0 (lowest level of health) to 100 (highest level of health) (20); anxiety, measured by the Generalized Anxiety Disorder Assessment (GAD-7), score range 0 (no anxiety) to 21 (severe anxiety) (21) and self-reported prescribed mental health medication.  Data were also collected on somatoform complaints, measured by the Patient Health Questionnaire-15 items (PHQ-15), score range 0 to 28 (higher scores indicate greater physical impairment, item on menstrual problems was excluded) (22); and psychological resilience, measured by the two-item Connor-Davidson Resilience Scale (CD-RISC2) which has a score range of 0 to 8, a higher score indicating greater psychological resilience (23), but these were not statistically evaluated.  Questionnaires were administered by researchers blinded to treatment allocation.  Resource use was ascertained from primary care records, and Quality Adjusted Life Years (QALYs) were measured using the EuroQol (EQ-5D-3L), score range 0 (death) to 1 (perfect health)(24) though the cost-effectiveness analysis is not reported here.  Death during follow-up was pre-specified as an outcome and measured via linkage to mortality data from the UK Office for National Statistics (ONS).  In our trial protocol we indicated that the number of falls would be recorded, but we decided not collect these data before the first participant was randomised.  

Sample size
In order to detect a small to medium standardised minimum effect size of 0.3 (based on a meta-analysis of previous trials of collaborative care,(25), corresponding to approximately 1.3 PHQ-9 score points) with 80% power and a two-sided 5% significance level, 352 patients were required (176 in each group).  Although this was an individually-randomised trial, the sample size was inflated to account for potential clustering around case managers and potential loss to follow-up of 25%.  The final sample size to be recruited was 658 patients, 329 in each group.

Statistical analysis
Primary analysis: Patients were analysed as part of the group to which they had been randomised (intention-to-treat) using a linear mixed model if they had valid primary outcome data at 4 or 12 months follow-up and a baseline PHQ-9 and SF-12 physical component score.  The primary analysis model included as fixed effects: time (4 or 12 months), treatment group and time-by-treatment interaction, adjusting for PHQ-9 depression at randomization and physical/functional limitations (SF-12 physical component score) at baseline.  The primary endpoint was the estimate of the intervention effect at 4 months.

Secondary Analyses of the Primary Outcome: To quantify the effect of the grouping by case managers, these were modelled separately in each treatment group.  Additional variables associated with PHQ-9 scores at 4 months (age, gender, GAD-7, PHQ-15, mental health medication use and previous history of depression based on M.I.N.I. responses) were included as covariates in the primary analysis model.  To investigate the effect of missing data on the treatment effect, any baseline variables associated with non-response at four months follow-up (i.e. no valid PHQ-9 score) were identified and included as covariates in the primary analysis model.  In light of the observed differential dropout a multiple imputation model of the primary analysis was additionally included.

Secondary Outcomes: Analysis of secondary outcomes was exploratory, and no adjustments for multiple testing were applied.  The estimate of the effect of the intervention on PHQ-9 scores at 12 months was extracted from the primary analysis model.  For the dichotomous outcome of depression diagnosis’ at follow-up (PHQ-9 ≥ 10), data were analysed by logistic regression with Poisson regression models to calculate adjusted relative risks.  For other exploratory continuous secondary outcomes (SF-12, GAD-7), statistical analyses were conducted using a similar model to the primary analysis.  Other collected data (PHQ-15 and CD-RISC2) were summarized descriptively.

Analyses used two-sided significance at the 5% level, and no adjustments for multiple comparisons were made.  All analyses were conducted in Stata version 13.1. The statistical analysis and reporting of the trial followed the Consolidated Standards of Reporting Trial (CONSORT) guidelines.(26).  The study followed a trial protocol and all analyses followed a pre-specified statistical analysis plan (see online supplement for (i) our study protocol and (ii) a detailed description of statistical analysis, with a description of any amendments to protocol).  


RESULTS
37,134 patients from 38 primary care centres were invited by letter between March 2011 and May 2013.  Of 6,693 patients who consented to be contacted and provided information about depressive symptoms, 4,259 were excluded (largely on the basis of negative results on the two-item depression screen), and 2,434 patients were assessed for eligibility by the MINI diagnostic interview.  705 (29%) patients were identified to have sub-threshold depression and were randomized into the trial; 58% female, mean age 77 (SD 7.1).  344 were allocated to collaborative care and 361 to usual care.  The remaining patients were either classified as fulfilling no criteria for depression (n=1,558, 64%) or as meeting criteria for major depressive disorder (MDD) (n=171, 7%) (see CONSORT diagram in Figure 1).  The primary outcome (PHQ-9 depression severity at 4 months) was available for 586 patients, equating to an actual loss to follow-up of 16.9% (23.8% in the collaborative care group and 10.2% in the usual care group).  At 12 months 519 patients were retained, with loss to follow up of 26.4% at 12 months (31.7% in the collaborative care group and 21.3% in the usual care group).


<Figure 1> CONSORT diagram

The randomised groups were comparable on trial entry (Table 1).  The median depression severity across both groups was 7, which was consistent with a low severity depression.(19)  Prescription rates of antidepressants were low at entry to the trial (collaborative care 10%, usual care 14%).

<Table 1>

Delivery of collaborative care intervention
Collaborative care was delivered by 18 case mangers (mean case load of 19.1 randomised patients).  Participants received on average six sessions (median: 7, minimum 1, maximum 15) over seven to eight weeks, of which two were delivered face-to-face, and four were delivered over the phone.  The average session duration was half an hour. 



Depression severity at follow-up
At the primary outcome of four months there was a between-group difference of -1.31 PHQ-9 score points (95% CI: -1.95 to -0.67, p<.001) equivalent to a standard effect size of 0.3 in favour of collaborative care.  At 12 months the exploratory between group difference remained (-1.33 PHQ-9 score points; 95% CI: -2.10 to -0.55, p=.001).  See Table 2 for full results, including sensitivity analyses.

<Table 2>

Depression diagnosis (PHQ9>=10)  at follow-up
The proportion of participants with a new depression diagnosis (PHQ-9 ≥ 10) at four and 12 months was lower in the collaborative care group, and this reached statistical significance at 12 months in exploratory analyses (four months: 17.2% vs 23.5%, difference = -6.3%. 95%CI -12.8, 0.2, Relative Risk = 0.83 , 95% CI: 0.61 to 1.27, p=0.247; 12 months: 15.7% vs. 27.8%, difference = -12.1%, 95%CI -19.1, -5.1, Relative Risk 0.65, 95%CI 0.46 to 0.91, p=0.013).  See Table 2.

Antidepressant use
Approximately 10% of patients in the collaborative care group were prescribed antidepressants at baseline, compared to 14% in the Usual Care group (Table 2). The exploratory relative risk of being prescribed antidepressants were no different at four months follow-up (Relative Risk: 0.73, 95% CI: 0.51 to 1.04, p=0.083) or at twelve months follow-up (Relative Risk: 0.84, 95% CI: 0.60 to 1.19, p=0.327).

Health Related Quality of Life
The physical health of patients was better for collaborative care in exploratory analyses (mean score differences: -2.83 at 4 months, 95% CI: -4.03 to -1.62, standard effect size d=0.2, p <.001; -1.67 at 12 months, 95% CI: -3.06 to -0.27 , d=0.1, p=.020 – see Figure 2 and table 2).  The mental health of patients was better for collaborative care in exploratory analyses (mean score differences: -1.88 at 4 months, 95% CI: -3.29 to -0.47 , d=0.2, p =.009; -2.15 at 12 months, 95% CI: -3.70 to -0.59, d=0.2, p=.007 – see Figure 2 and table 2).

Anxiety  
Significant exploratory between group differences in anxiety symptoms (GAD-7) were observed in favour of collaborative care at four months (mean score difference: -1.08, 95% CI: -1.64 to -0.52, d=0.3, p<.001) and at twelve months (mean score difference: -1.01, 95% CI: -1.61 to -0.42, d=0.2, p=.001).  See Figure 2 and Table 2.  

Somatoform complaints
Physical health problems (PHQ-15) improved especially at four months for collaborative care patients in exploratory analyses.  Symptoms for which the greatest improvements were observed were: pain in arms, legs or joints; dizziness; shortness of breath; constipation, loose bowels or diarrhoea; and trouble sleeping.  See Figure 2.

Resilience
Participants in the collaborative care group improved average resilience (CD-RISC2) to above 6 score points, and the difference between the treatment groups was most pronounced at four months follow-up.

<Figure 2>

Adverse events - mortality
A total of 23 participants died during 12-month follow-up-, 5 patients in the collaborative care group (1.5% of randomised patients) and 18 patients in the usual care group (5.0% of randomised patients) which was statistically significant (1=6.97, p =.008).  All causes of death and their potential relatedness to the trial treatment were assessed independently and presented to the Data Monitoring and Ethics Committee (DMEC) in line with our procedures for serious adverse events.  Approximately 81% of deaths were categorised as being unrelated to treatment, and 18% as unlikely to be related to treatment.  The DMEC committee assessed that the recorded causes of death could not be reasonably attributed to either the intervention or control treatment.  The exploratory observed group difference in mortality is therefore treated as a chance result.

DISCUSSION
The main finding from this randomized trial is that a collaborative care intervention reduced the PHQ-9 score at four month follow-up, compared to usual care.  The PHQ-9 score was also lower at 12-month follow-up in the collaborative care group, but high attrition rates reduce confidence in this result.  For populations with case level depression a successful treatment outcome has been defined as five points on the PHQ9.(28)  We did not observe this in either group of the trial when comparing scores before and after treatment though this would be anticipated in view of the lower baseline PHQ9 scores in populations with subthreshold depression.  The between-group difference was 1.31 PHQ9 points which is a small to medium effect size according to Cohen (9, 27) and consistent with the Cochrane meta-analysis of collaborative care(11), but is not large when judged against a clinical difference of 5 points advocated in more severe disorders (see (29)).  Collaborative care also prevented the onset of depression diagnosis (as ascertained by the PHQ9) by 12.1% at 12 months, but was non-significant at 4 months in an exploratory analysis.  

The treatment of older people with subthreshold depression is an under-researched topic and the trial is a major contribution to randomized evidence in this area.  The results of the trial are consistent with other research into collaborative care for depression in older people. ADDIN EN.CITE (11, 17, 30)  However there have been very few studies to date that have examined the effectiveness of collaborative care in older people and explored the ability to prevent lower severity depression symptoms progressing to the point of case level depression.  Behavioural activation is also a relatively simple type of treatment that could be taught to and administered by a wide range of health care professionals.(31)  We note a reduction in mortality for people who received collaborative care, but independent case by case review of deaths was not thought to be linked to the intervention.  This was an unexpected finding and one which deserves further study in future trials.  We have considered the possibility that people randomized to the control group were more unwell and that this might have influenced the primary outcome.  We think this explanation unlikely since the numbers who died were small in relation to the size of the trial and there was evidence of balance between groups at baseline on measures of symptoms severity and quality of life.  We note that all secondary outcomes are also exploratory.  

There were several limitations to the study.  The ascertainment of depression diagnosis was exploratory and not ascertained using a standardised diagnostic interview, although the PHQ-9 has now been extensively validated against interview based DSM-IV Major Depressive Disorder.(32)  Retention and differential attrition between the trial groups was a further limitation.  There was a higher rate of attrition in the collaborative care group (24%) compared to the usual care group (10%).  Participants who wished to discontinue the collaborative care intervention fully withdrew from the trial at the same time, including follow-up.  It remains possible therefore participants who withdrew may have presented a different outcome profile to those who continued, which may have biased the treatment effect.  The results of the trial were robust using various multiple imputation approaches to missing data.  However this was a potential source of bias and unequal loss to follow up could have influenced our results.  A final limitation is that there was no follow-up after 12 months.

Conclusions and relevance
Among older adults with sub-threshold depression, collaborative care compared with usual care resulted in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain clinical importance. Although differences persisted through 12 months, findings are limited by attrition, and further research is needed to assess longer-term efficacy.
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Table 1: Baseline characteristics
Characteristic	As Randomised	As Analysed*
	Collaborative Care(N=344)	Usual Care(N=361)	Collaborative Care(N=274)	Usual Care(N=327)
Age at consent (in years)				
  N	344 (100.0%)	361 (100.0%)	274 (100.0%)	327 (100.0%)
  Mean (SD)	77.1 (7.08)	77.5 (7.18)	76.6 (7.21)	77.4 (7.13)
  Median  (min, max)	77 (65, 96)	78 (64, 93)	77 (65, 93)	78 (64, 93)
Gender				
  Male	159 (46.2%)	139 (38.5%)	122 (44.5%)	123 (37.6%)
  Female	185 (53.8%)	222 (61.5%)	152 (55.5%)	204 (62.4%)
Educated past 16 years of age	180 (52.3%)	186 (51.5%)	146 (53.3%)	168 (51.4%)
Degree or equivalent professional qualification	115 (33.4%)	106 (29.4%)	95 (34.7%)	96 (29.4%)
Smoking (yes)	16 (4.7%)	29 (8.0%)	12 (4.4%)	25 (7.6%)
Three or more alcohol units/day (one unit equals 10ml of pure alcohol)	32 (9.3%)	21 (5.8%)	26 (9.5%)	16 (4.9%)
Ethnicity				
  White	340 (98.8%)	358 (99.2%)	271 (98.9%)	324 (99.1%)
  Asian or Asian British	2 (0.6%)	0 (0.0%)	2 (0.7%)	0 (0.0%)
  Black or Black British	0 (0.0%)	2 (0.6%)	0 (0.0%)	2 (0.6%)
  Other	1 (0.3%)	0 (0.0%)	1 (0.4%)	0 (0.0%)
Fallen in the last 12 months				
  Yes	110 (32.0%)	142 (39.3%)	89 (32.5%)	131 (40.1%)
  No	224 (65.1%)	212 (58.7%)	176 (64.2%)	190 (58.1%)
  Can’t recall	8 (2.3%)	5 (1.4%)	8 (2.9%)	4 (1.2%)
Health problems				
  Diabetes	55 (16.0%)	66 (18.3%)	43 (15.7%)	64 (19.6%)
  Osteoporosis	33 (9.6%)	42 (11.6%)	27 (9.9%)	40 (12.2%)
  High blood pressure	157 (45.6%)	174 (48.2%)	131 (47.8%)	160 (48.9%)
  Rheumatoid arthritis 	38 (11.0%)	57 (15.8%)	31 (11.3%)	53 (16.2%)
  Osteoarthritis 	98 (28.5%)	114 (31.6%)	81 (29.6%)	106 (32.4%)
  Stroke	28 (8.1%)	31 (8.6%)	22 (8.0%)	27 (8.3%)
  Cancer	49 (14.2%)	37 (10.2%)	38 (13.9%)	34 (10.4%)
  Respiratory conditions	65 (18.9%)	81 (22.4%)	51 (18.6%)	73 (22.3%)
  Eye condition	130 (37.8%)	136 (37.7%)	98 (35.8%)	117 (35.8%)
  Heart disease	88 (25.6%)	86 (23.8%)	66 (24.1%)	75 (22.9%)
  Other	74 (21.5%)	74 (20.5%)	64 (23.4%)	65 (19.9%)
PHQ-9 (0-27, higher score indicates worse depression)				
  N	340 (98.8%)	358 (99.2%)	274 (100.0%)	327 (100.0%)
  Mean (SD)	7.8 (4.71)	7.8 (4.64)	7.6 (4.32)	7.6 (4.55)
  Median (min, max)	7 (0, 27)	7 (0, 25)	7 (0, 27)	7 (0, 25)
PHQ-15 (0-28, higher score indicates worse physical symptoms)				
  N	339 (98.5%)	356 (98.6%)	274 (100.0%)	326 (99.7%)
  Mean (SD)	9.1 (4.12)	9.5 (3.94)	9.1 (4.17)	9.4 (3.93)
  Median (min, max)	9 (0, 25)	9 (0, 20)	9 (0, 25)	9 (0, 20)
SF-12 (Physical Component, 0-100, higher score indicates better physical health)				
  N	337 (98.0%)	356 (98.6%)	274 (100.0%)	327 (100.0%)
  Mean (SD)	38.0 (13.37)	36.5 (13.02)	38.5 (13.15)	36.6 (13.11)
  Median (min, max)	37.5 (4.6, 69.9)	35.1 (5.7, 66.6)	38.1 (4.6, 69.9)	35 (5.7, 66.6)
SF-12 (Mental Component, 0-100, higher score indicates better mental health)				
  N	337 (98.0%)	356 (98.6%)	274 (100.0%)	327 (100.0%)
  Mean (SD)	44.3 (10.96)	45.1 (10.02)	44.5 (10.97)	45.2 (10.04)
  Median (min, max)	44.9 (12.5, 66.0)	46.3 (9.6, 67.0)	45.1 (12.5, 66.0)	46.5 (9.6, 67.0)
GAD-7 (0-21, higher score indicates worse anxiety)				
  N	340 (98.8%)	358 (99.2%)	274 (100.0%)	327 (100.0%)
  Mean (SD)	5.7 (4.82)	5.7 (4.45)	5.5 (4.58)	5.6 (4.38)
Self-report of any prescribed mental health medication	35 (10.2%)	51 (14.1%)	29 (10.6%)	46 (14.1%)
* As analysed: All patients included in the primary analysis, i.e. patients with a valid PHQ-9 score at 4 or 12 months follow-up and valid covariate data (PHQ-9 score at randomisation and baseline SF-12 Physical Component Score)


Table 2: Summary of between-group differences

Estimate at	Collaborative Care 	Usual Care 	Group Difference 
	N	Mean	(95% CI)	N	Mean	(95% CI)	Mean	(95% CI)	p
PHQ-9: Primary analysis1 (0-27, higher score indicates worse depression)
4 months*	274	5.36	(4.89, 5.83)	327	6.67	(6.24, 7.10)	-1.31	(-1.95, -0.67)	<.001
12 months	274	5.93	(5.35, 6.50)	327	7.25	(6.73, 7.77)	-1.33	(-2.10, -0.55)	.001
PHQ-9: Analysis adjusted for clustering by case manager2, (0-27, higher score indicates worse depression)
4 months	274	5.46	(4.80, 6.11)	327	6.67	(6.23, 7.11)	-1.21	(-1.99, -0.42)	.003
12 months	274	6.03	(5.30, 6.76)	327	7.24	(6.71, 7.78)	-1.21	(-2.12, -0.31)	.008
PHQ-9: Analysis using multiply imputed data3 (0-27, higher score indicates worse depression)
4 months	344	5.40	(4.94, 5.85)	361	6.80	(6.36, 7.23)	-1.40	(-2.04, -0.76)	<.001
12 months	344	6.01	(5.43, 6.60)	361	7.26	(6.73, 7.79)	-1.25	(-1.99, -0.50)	.001
PHQ-9: Unadjusted means (0-27, higher score indicates worse depression)
4 months	262	5.17	(4.67, 5.68)	324	6.75	(6.26, 7.24)	-1.58	-	-
12 months	235	5.67	(5.09, 6.24)	284	7.23	(6.65, 7.82)	-1.57	-	-
	N	Total	%	N	Total	%	RR5	(95% CI)	p
Proportion of patients with moderate to severe PHQ-9 depression4, 5, (Exploratory) (PHQ9 score ≥10)
4 months	45	262	17.2	76	324	23.5	0.83	(0.61, 1.27)	.247
12 months	37	235	15.7	79	284	27.8	0.65	(0.46, 0.91)	.013
Proportion of patients with prescribed antidepressants6 (Exploratory)
4 months	26	264	9.9	46	321	14.3	0.73	(0.51, 1.04)	.083
12 months	23	234	9.8	44	281	15.7	0.84	(0.60, 1.19)	.327
	N	Mean	(95% CI)	N	Mean	(95% CI)	Mean	(95% CI)	p
SF-12 Physical Component Score (PCS)7 (Exploratory) (0-100, higher score indicates better physical health)
4 months	263	38.8	(37.7, 39.9)	316	36.0	(35.0, 37.0)	2.83	(1.62, 4.03)	<.001
12 months	263	37.8	(36.6, 39.0)	316	36.1	(35.0, 37.2)	1.67	(0.27, 3.06)	.020
SF-12 Mental Component Score (MCS)7 (Exploratory) (0-100, higher score indicates better mental health)
4 months	263	47.6	(46.3, 48.9)	316	45.7	(44.6, 46.9)	1.88	(0.47, 3.29)	.009
12 months	263	46.8	(45.4, 48.1)	316	44.6	(43.4, 45.9)	2.15	(0.59, 3.70)	.007
GAD-7 Anxiety8 (Exploratory) (0-21, higher score indicates worse anxiety)
4 months	264	4.05	(3.54, 4.55)	315	5.13	(4.67, 5.59)	-1.08	(-1.64, -0.52)	<.001
12 months	264	4.18	(3.66, 4.71)	315	5.20	(4.72, 5.67)	-1.01	(-1.61, -0.42)	.001
* Primary endpoint
1 Primary analysis: Linear mixed effects model adjusted for treatment group, time (4 & 12 months), group x time interaction, PHQ-9 at randomisation and baseline SF-12 Physical Component Score, including unstructured residual variances and covariance over time
2 As primary analysis model, additionally including case manager as random effect
3 As primary analysis model, using data derived by multiple imputation based on predictors: allocation, age at consent, PHQ-9 at randomisation, baseline SF-12 Physical Component Score, baseline SF-12 Mental Component Score, baseline GAD-7, prescribed antidepressants at baseline (yes/no) and baseline PHQ-15
4 Relative risk (RR) of the outcome for collaborative care compared with usual care. RR > 1 indicates collaborative care increases risk of event; RR < 1 indicates collaborative care decreases risk of event.
5 PHQ-9 self-reported depression severity, score range 0-27, moderate to severe depression defined as scores ≥10
6 Individual logistic regressions, adjusted for treatment group, PHQ-9 at randomisation, baseline SF-12 Physical Component Score, prescribed antidepressants at baseline (yes/no), baseline GAD-7 and baseline PHQ-15
7 Linear mixed effects model adjusted for treatment group, time (4 & 12 months), group x time interaction, PHQ-9 at randomisation, baseline SF-12 mental component score, baseline SF-12 physical component score, prescribed antidepressants at baseline (yes/no), baseline GAD-7 and baseline PHQ-15, including unstructured residual variances and covariance over time
8 Linear mixed effects model adjusted for treatment group, time (4 & 12 months), group x time interaction, PHQ-9 at randomisation, baseline GAD-7, baseline SF-12 physical component score, prescribed antidepressants at baseline (yes/no) and baseline PHQ-15, including unstructured residual variances and covariance over time
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